NCT04816019View on ClinicalTrials.gov

A Study of Intranasal ChAdOx1 nCOV-19

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

September 30, 2022

Study Completion Date

September 30, 2022

Conditions
Coronavirus
Interventions
BIOLOGICAL

ChAdOx1 nCov-19

A single dose of ChAdOx1 nCov-19 delivered intranasally (IN)

Trial Locations (1)

OX3 7LE

CCVTM, University of Oxford, Churchill Hospital, Oxford

All Listed Sponsors
lead

University of Oxford

OTHER

NCT04816019 - A Study of Intranasal ChAdOx1 nCOV-19 | Biotech Hunter | Biotech Hunter